Core Viewpoint - China Traditional Chinese Medicine (00570.HK) is expected to report a net loss of approximately RMB 350 million to RMB 500 million for the fiscal year ending December 31, 2025, a significant decline from a net profit of RMB 20.77 million in the previous year [1] Group 1: Financial Performance - The company anticipates a transition from profit to loss, with the expected net loss range being RMB 350 million to RMB 500 million compared to a net profit of RMB 20.77 million in the same period last year [1] - Adjusted net profit is projected to decline by 45% to 55% year-on-year, with the previous year's figure being approximately RMB 636 million [1] Group 2: Reasons for Financial Changes - The primary reasons for the transition from profit to loss include: - A decrease in revenue and profitability in the Chinese medicine formula granule business due to increased market competition and a higher proportion of centralized procurement [1] - An increase in impairment of goodwill, intangible assets, and credit losses during the current period [1] - Adjusted net profit is calculated after excluding the impacts of: - Impairment of goodwill and related asset groups [1] - Tax payments owed by certain subsidiaries [1]
中国中药(00570.HK)：预计2025年度亏损净额区间预计约为3.5亿元至5亿元